ZNTL
Zentalis Pharmaceuticals Llc
NASDAQ: ZNTL · HEALTHCARE · BIOTECHNOLOGY
$4.01
+1.26% today
Updated 2026-04-30
Market cap
$287.27M
P/E ratio
—
P/S ratio
7.13x
EPS (TTM)
$-1.91
Dividend yield
—
52W range
$1 – $7
Volume
2.2M
Zentalis Pharmaceuticals Llc (ZNTL) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-24.25M | $-39.14M | $-86.83M | $-154.09M | $-163.75M | $-207.82M | $-170.86M | $-125.25M |
| Capital expenditures | $227000.00 | $352000.00 | $758000.00 | $6.11M | $2.55M | $583000.00 | $221000.00 | $0.00 |
| Depreciation | $51000.00 | $111000.00 | $160000.00 | $544000.00 | $1.43M | $1.39M | $1.29M | — |
| Stock-based comp | $308000.00 | $617000.00 | $23.15M | $35.74M | $46.84M | $54.82M | $67.27M | $20.72M |
| Free cash flow | $-24.48M | $-39.49M | $-87.58M | $-160.20M | $-166.30M | $-208.41M | $-171.08M | $-125.25M |
| Investing cash flow | $-227000.00 | $-352000.00 | $-284.83M | $-18.11M | $-114.18M | $-44.46M | $176.56M | — |
| Financing cash flow | $9.47M | $81.83M | $360.44M | $178.52M | $261.04M | $237.30M | $108000.00 | — |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $-11.22M | $6.31M | $-16.89M | — | — | — |